Argument & Sources

Should access to GLP-1 weight-loss drugs be publicly reimbursed?

Public coverage for semaglutide and similar treatments.

14 votes|10 arguments|0 source

50%7

2/5 Arguments

Trial data show 15–20% sustained weight loss, with major reductions in cardiovascular events — comparable to statins as preventive medicine. @@yes_2

Comparative overview of how surrogacy is regulated across 46 European jurisdictions, from outright bans to fully commercial frameworks.